{"id":"https://openalex.org/W2001483085","doi":"https://doi.org/10.7326/0003-4819-127-5-199709010-00001","title":"Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease: A Meta-Analysis of Randomized Trials","display_name":"Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease: A Meta-Analysis of Randomized Trials","publication_year":1997,"publication_date":"1997-09-01","ids":{"openalex":"https://openalex.org/W2001483085","doi":"https://doi.org/10.7326/0003-4819-127-5-199709010-00001","mag":"2001483085","pmid":"https://pubmed.ncbi.nlm.nih.gov/9273824"},"language":"en","primary_location":{"id":"doi:10.7326/0003-4819-127-5-199709010-00001","doi":"https://doi.org/10.7326/0003-4819-127-5-199709010-00001","is_oa":false,"landing_page_url":"https://doi.org/10.7326/0003-4819-127-5-199709010-00001","pdf_url":null,"source":{"id":"https://openalex.org/S119722071","display_name":"Annals of Internal Medicine","issn_l":"0003-4819","issn":["0003-4819","1539-3704"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316812","host_organization_name":"American College of Physicians","host_organization_lineage":["https://openalex.org/P4310316812"],"host_organization_lineage_names":["American College of Physicians"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Internal Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041072634","display_name":"Ioannis Giatras","orcid":"https://orcid.org/0000-0002-2210-6725","observed_orcids":["https://orcid.org/0000-0002-2210-6725"]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]},{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ioannis Giatras","raw_affiliation_strings":["*For members of the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, see Appendix","For the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group*","From New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts","Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996; 7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group  has been published (Lancet. 1997; 349:1857-63); this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death","349:1857-63)","7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group [16] has been published (Lancet. 1997","Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996","this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*For members of the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, see Appendix","institution_ids":[]},{"raw_affiliation_string":"For the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group*","institution_ids":[]},{"raw_affiliation_string":"From New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts","institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"]},{"raw_affiliation_string":"Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996; 7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group  has been published (Lancet. 1997; 349:1857-63); this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death","institution_ids":[]},{"raw_affiliation_string":"349:1857-63)","institution_ids":[]},{"raw_affiliation_string":"7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group [16] has been published (Lancet. 1997","institution_ids":[]},{"raw_affiliation_string":"Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996","institution_ids":[]},{"raw_affiliation_string":"this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Joseph Lau","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]},{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Lau","raw_affiliation_strings":["*For members of the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, see Appendix","For the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group*","From New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts","Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996; 7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group  has been published (Lancet. 1997; 349:1857-63); this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*For members of the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, see Appendix","institution_ids":[]},{"raw_affiliation_string":"For the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group*","institution_ids":[]},{"raw_affiliation_string":"From New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts","institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"]},{"raw_affiliation_string":"Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996; 7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group  has been published (Lancet. 1997; 349:1857-63); this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032690087","display_name":"Andrew S. Levey","orcid":"https://orcid.org/0000-0003-1491-501X","observed_orcids":["https://orcid.org/0000-0003-1491-501X"]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]},{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew S. Levey","raw_affiliation_strings":["*For members of the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, see Appendix","For the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group*","From New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts","Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996; 7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group  has been published (Lancet. 1997; 349:1857-63); this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*For members of the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, see Appendix","institution_ids":[]},{"raw_affiliation_string":"For the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group*","institution_ids":[]},{"raw_affiliation_string":"From New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts","institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"]},{"raw_affiliation_string":"Note added in proof: Since submission of the manuscript, the unpublished report by van Essen and colleagues has been published in abstract form (J Am Soc Nephrol. 1996; 7:1400), and a full-length article is in press (Kidney Int Suppl). In addition, a study by the GISEN group  has been published (Lancet. 1997; 349:1857-63); this study showed a beneficial effect of ramipril in nondiabetic renal disease. Including the GISEN group results in our meta-analysis does not substantially change the results. The pooled relative risks in the 11 studies are 0.69 (CI, 0.53 to 0.91) for end-stage renal disease and 1.32 (CI, 0.61 to 2.88) for death","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5041072634"],"corresponding_institution_ids":["https://openalex.org/I121934306","https://openalex.org/I1290900354"],"apc_list":null,"apc_paid":null,"fwci":32.0655,"has_fulltext":false,"cited_by_count":422,"citation_normalized_percentile":{"value":0.99904215,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"127","issue":"5","first_page":"337","last_page":"345"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.7153000235557556,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.7153000235557556,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.1234000027179718,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.08129999786615372,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":1.0},{"id":"https://openalex.org/keywords/non-diabetic-renal-disease","display_name":"non-diabetic kidney disease","score":0.9639999866485596},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.9599999785423279},{"id":"https://openalex.org/keywords/renal-function-decline","display_name":"renal function decline","score":0.7350000143051147},{"id":"https://openalex.org/keywords/antihypertensive-drugs","display_name":"antihypertensive drugs","score":0.9340000152587891},{"id":"https://openalex.org/keywords/blood-pressure-reduction","display_name":"blood pressure reduction","score":0.8259999752044678},{"id":"https://openalex.org/keywords/mortality","display_name":"mortality","score":0.9589999914169312},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.40799999237060547}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9294483065605164},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6117306351661682},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6074539422988892},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.6031203269958496},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.5871078372001648},{"id":"https://openalex.org/C27016395","wikidata":"https://www.wikidata.org/wiki/Q128861","display_name":"Angiotensin-converting enzyme","level":3,"score":0.5701317191123962},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5324699878692627},{"id":"https://openalex.org/C3019040382","wikidata":"https://www.wikidata.org/wiki/Q476921","display_name":"End stage renal disease","level":3,"score":0.47561365365982056},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.4133971333503723},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.39520347118377686},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3504534959793091},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.33559703826904297}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000806","descriptor_name":"Angiotensin-Converting Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007674","descriptor_name":"Kidney Diseases","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012306","descriptor_name":"Risk","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.7326/0003-4819-127-5-199709010-00001","doi":"https://doi.org/10.7326/0003-4819-127-5-199709010-00001","is_oa":false,"landing_page_url":"https://doi.org/10.7326/0003-4819-127-5-199709010-00001","pdf_url":null,"source":{"id":"https://openalex.org/S119722071","display_name":"Annals of Internal Medicine","issn_l":"0003-4819","issn":["0003-4819","1539-3704"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316812","host_organization_name":"American College of Physicians","host_organization_lineage":["https://openalex.org/P4310316812"],"host_organization_lineage_names":["American College of Physicians"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Internal Medicine","raw_type":"journal-article"},{"id":"pmid:9273824","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9273824","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of internal medicine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[{"id":"https://openalex.org/G2544763378","display_name":null,"funder_award_id":"R01-HS07782","funder_id":"https://openalex.org/F4320332177","funder_display_name":"Agency for Healthcare Research and Quality"},{"id":"https://openalex.org/G4446118911","display_name":null,"funder_award_id":"R01 HS08532","funder_id":"https://openalex.org/F4320332177","funder_display_name":"Agency for Healthcare Research and Quality"}],"funders":[{"id":"https://openalex.org/F4320332177","display_name":"Agency for Healthcare Research and Quality","ror":"https://ror.org/03jmfdf59"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7099304666","https://openalex.org/W2001171291","https://openalex.org/W1984787550","https://openalex.org/W7075614437","https://openalex.org/W2170453602","https://openalex.org/W2068301327","https://openalex.org/W2066051647","https://openalex.org/W2088172412","https://openalex.org/W1970400657","https://openalex.org/W4241523619"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,48,158,187],"effect":[2,29,248],"of":[3,30,36,79,85,96,229,262],"angiotensin-converting":[4],"enzyme":[5,216],"(ACE)":[6],"inhibitors":[7,32,68,217],"in":[8,12,15,99,145,189,207,225,255],"slowing":[9],"the":[10,28,34,146,149,181,208,227,252],"decline":[11,254],"renal":[13,17,38,87,90,109,139,171,232],"function":[14],"nondiabetic":[16,231],"disease":[18,39,88,140,172],"varies":[19],"among":[20],"studies.":[21,59],"PURPOSE:":[22],"To":[23],"use":[24],"meta-analysis":[25],"to":[26,167,177,251,259],"assess":[27],"ACE":[31,67,133,212,263],"on":[33,107],"development":[35,228],"end-stage":[37,108,138,170,230],"caused":[40],"by":[41,53],"factors":[42],"other":[43,70,222,260],"than":[44,221],"diabetes.":[45],"DATA":[46,104,127],"SOURCES:":[47],"English-language":[49],"medical":[50],"literature,":[51],"identified":[52],"a":[54],"MEDLINE":[55],"search":[56],"and":[57,73,89,114,123,141,155,173,193,201,234],"unpublished":[58],"STUDY":[60],"SELECTION:":[61],"All":[62],"randomized":[63],"studies":[64,101,182],"that":[65],"compared":[66],"with":[69],"antihypertensive":[71,223],"agents":[72,224],"had":[74],"at":[75],"least":[76],"1":[77],"year":[78],"planned":[80],"follow-up":[81,198],"were":[82,92,117,152,162,183,199],"selected.":[83],"Studies":[84],"diabetic":[86],"transplants":[91],"excluded.":[93],"A":[94],"total":[95],"1594":[97],"patients":[98,131,209],"10":[100],"was":[102],"included.":[103],"EXTRACTION:":[105],"Data":[106],"disease,":[110,233],"death,":[111],"drop":[112],"out,":[113],"blood":[115,195,256],"pressure":[116,257],"extracted.":[118],"Study":[119],"investigators":[120],"confirmed":[121],"results":[122],"provided":[124],"additional":[125],"data.":[126],"SYNTHESIS:":[128],"Among":[129],"806":[130],"receiving":[132],"inhibitors,":[134],"52":[135],"(6.4%)":[136],"developed":[137],"17":[142],"(2.1%)":[143],"died;":[144],"788":[147],"controls,":[148],"respective":[150],"values":[151],"72":[153],"(9.1%)":[154],"12":[156],"(1.5%).":[157],"pooled":[159],"relative":[160],"risks":[161],"0.70":[163],"(95%":[164],"CI,":[165],"0.51":[166],"0.97)":[168],"for":[169,179],"1.24":[174],"(CI,":[175],"0.55":[176],"2.83)":[178],"death;":[180],"not":[184,237,242],"significantly":[185],"heterogeneous.":[186],"decreases":[188],"weighted":[190],"mean":[191],"systolic":[192],"diastolic":[194],"pressures":[196],"during":[197],"4.9":[200],"1.2":[202],"mm":[203],"Hg":[204],"greater,":[205],"respectively,":[206],"who":[210],"received":[211],"inhibitors.":[213],"CONCLUSIONS:":[214],"Angiotensin-converting":[215],"are":[218],"more":[219],"effective":[220],"reducing":[226],"they":[235],"do":[236],"increase":[238],"mortality.":[239],"It":[240],"could":[241],"be":[243],"determined":[244],"whether":[245],"this":[246],"beneficial":[247],"is":[249],"due":[250],"greater":[253],"or":[258],"effects":[261],"inhibition.":[264]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":5},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}